Table 2. Inflammation, immune activation, immunological and virological evolution following the end of 4th STI (week 0) until week 48 of follow-up.
| Week 0 (end 4th STI) | End of ART (final STOP) | Week 24 | Week 48 | |||||
|---|---|---|---|---|---|---|---|---|
| CD4 (cells/mm3) | ||||||||
| STI group | 622 | (514–1,167) | 1,116 | (669–1,297) | 928 | (601–1,079) | 668 | (514–1,033) |
| IL-2 group | 613 | (278–864) | 933 | (559–1092) | 865 | (832–906) | 690 | (669–936) |
| CD4/CD8 ratio | ||||||||
| STI group | 1.05 | (0.90–1.60) | 1.55 | (0.80–1.60) | 1.35 | (1.00–1.55) | 1.05 | (0.75–1.30) |
| IL-2 group | 0.83 | (0.77–1.00) | 1.1 | (0.92–1.87) | 0.93 | (0.67–1.28) | 0.77 | (0.48–0.87) |
| CD8/CD28+ (%) | ||||||||
| STI group | 57 | (37–60) | 56 | (39–65) | 59 | (33–61) | 52 | (34–62) |
| IL-2 group | 49 | (36–64) | 38 | (34–58) | 47 | (26–50) | 51 | (42–53) |
| CD8/CD38+ (%) | ||||||||
| STI group | 57 | (52–64) | 47 | (52–64)* | 47 | (52–64) | 53 | (44–63) |
| IL-2 group | 46 | (36–57) | 61 | (53–67)* | 56 | (53–69) | 47 | (44–59) |
| HIV Viral Load (log10/mL) | ||||||||
| STI group | 4.13 | (3.64–4.64) | <1.30 | 3.36 | (2.89–3.93) | 4.26 | (4.15–4.60) | |
| IL-2 group | 3.98 | (2.96–4.83) | <1.30 | 4.52 | (3.76–5.08) | 4.58 | (4.19–5.01) | |
| HIV Viral Load<3000 copies/mL | ||||||||
| STI group | 2 (33%) | N/A | 2(33%) | 1(17%) | ||||
| IL-2 group | 3 (50%) | N/A | 2(33%) | 0 | ||||
| TNF levels (pg/mL) | ||||||||
| STI group | 30 | (29–33) | 24 | (21–26)* | 26 | (16–29)* | 19 | (17–32) |
| IL-2 group | 36 | (21–42) | 39 | (37–49)* | 42 | (27–73)* | 44 | (29–64) |
| srIL-2 (pM) | ||||||||
| STI group | 61 | (61–82) | 59 | (35–60)* | 60 | (39–67)* | 76 | (39–91) |
| IL-2 group | 76 | (42–104) | 124 | (116–249)* | 124 | (101–127)* | 114 | (101–132) |
| Specific CD4 responses (positive antigen-specific anti-P24 protein responses) number of patients/total patients | ||||||||
| STI group | 2 out of 6 | 1 out of 6 | none | |||||
| IL-2 group | 1 out of 6 | 2 out of 6 | 1 out of 6 | |||||
| Specific CD8 responses (>500 SFC/10E6 PBMC) number of patients/total patients | ||||||||
| STI group | 4 out of 6* | 1 out of 6 | none | |||||
| IL-2 group | none* | none | none | |||||
Values are median and IQR
*p<0.05
ART: Antiretroviral treatment
STI: structured treatment interruptions
srIL-2: seric receptor for IL-2
SFC: Spot Forming Cells
PBMC: Peripheral blood mononuclear cells